-
公开(公告)号：US12109267B2
公开(公告)日：2024-10-08
申请号：US17979309
申请日：2022-11-02
IPC分类号： A61K39/395 , A61K9/00 , A61K47/18 , A61K47/26 , C07K16/24
CPC分类号： A61K39/39591 , A61K9/0019 , A61K47/183 , A61K47/26 , C07K16/241 , C07K2317/21 , C07K2317/76
摘要： The present invention relates to novel liquid pharmaceutical compositions of adalimumab, which include adalimumab or a biosimilar thereof, an histidine buffering agent such as histidine (or histidine buffer system such as histidine/imidazolium-histidine), and a sugar stabiliser such as trehalose. Such a combination of components furnishes formulations having a stability (e.g. on storage and when exposed to stress) which is comparable to or an improvement upon those known in the art, and with fewer ingredients. Such advances will help adalimumab treatments to become more widely available at lower cost, and prolong the viability of pre-loaded delivery devices (e.g. pre-filled syringes) to reduce unnecessary waste of the drug.
-
公开(公告)号：US20210030871A1
公开(公告)日：2021-02-04
申请号：US17069118
申请日：2020-10-13
摘要： The present invention relates to novel liquid pharmaceutical compositions of adalimumab, which include adalimumab or a biosimilar thereof, an acetate buffering agent/system such as sodium acetate/acetic acid, and a sugar stabiliser such as trehalose. Such a combination of components furnishes formulations having a stability (e.g. on storage and when exposed to stress) which is comparable to or an improvement upon those known in the art, and with fewer ingredients. Such advances will help adalimumab treatments to become more widely available at lower cost, and prolong the viability of pre-loaded delivery devices (e.g. pre-filled syringes) to reduce unnecessary waste of the drug.
-
公开(公告)号：US20200155677A1
公开(公告)日：2020-05-21
申请号：US16584418
申请日：2019-09-26
IPC分类号： A61K39/395 , A61K47/26 , A61K47/12 , C07K16/24 , A61K9/00
摘要： The present invention relates to novel liquid pharmaceutical compositions of adalimumab, which include adalimumab or a biosimilar thereof, a citrate buffering agent/system such as sodium citrate/citric acid, and a sugar stabiliser such as trehalose. Such a combination of components furnishes formulations having a stability (e.g. on storage and when exposed to stress) which is comparable to or an improvement upon those known in the art, and with fewer ingredients. Such advances will help adalimumab treatments to become more widely available at lower cost, and prolong the viability of pre-loaded delivery devices (e.g. pre-filled syringes) to reduce unnecessary waste of the drug.
-
公开(公告)号：US10426832B2
公开(公告)日：2019-10-01
申请号：US15313470
申请日：2015-05-15
IPC分类号： A61K39/00 , A61K39/395 , A61K9/00 , A61K47/26 , A61K9/19 , C07K16/24 , A61K47/02 , A61K47/12
摘要： The present invention relates to novel liquid pharmaceutical compositions of adalimumab, which include adalimumab or a biosimilar thereof, an acetate buffering agent/system such as sodium acetate/acetic acid, and a sugar stabilizer such as trehalose. Such a combination of components furnishes formulations having a stability (e.g. on storage and when exposed to stress) which is comparable to or an improvement upon those known in the art, and with fewer ingredients. Such advances will help adalimumab treatments to become more widely available at lower cost, and prolong the viability of pre-loaded delivery devices (e.g. pre-filled syringes) to reduce unnecessary waste of the drug.
-
公开(公告)号：US11712471B2
公开(公告)日：2023-08-01
申请号：US17069118
申请日：2020-10-13
IPC分类号： A61K6/00 , C07K1/00 , A61K39/395 , A61K9/00 , A61K47/26 , C07K16/24 , A61K9/19 , A61K47/02 , A61K47/12 , A61K39/00
CPC分类号： A61K39/39591 , A61K9/0019 , A61K9/19 , A61K47/02 , A61K47/12 , A61K47/26 , C07K16/241 , A61K2039/505 , A61K2039/54 , C07K2317/21 , C07K2317/76
摘要： The present invention relates to novel liquid pharmaceutical compositions of adalimumab, which include adalimumab or a biosimilar thereof, an acetate buffering agent/system such as sodium acetate/acetic acid, and a sugar stabiliser such as trehalose. Such a combination of components furnishes formulations having a stability (e.g. on storage and when exposed to stress) which is comparable to or an improvement upon those known in the art, and with fewer ingredients. Such advances will help adalimumab treatments to become more widely available at lower cost, and prolong the viability of pre-loaded delivery devices (e.g. pre-filled syringes) to reduce unnecessary waste of the drug.
-
公开(公告)号：US11197930B2
公开(公告)日：2021-12-14
申请号：US17069118
申请日：2020-10-13
IPC分类号： A61K6/00 , C07K1/00 , A61K39/395 , A61K9/00 , A61K47/26 , C07K16/24 , A61K9/19 , A61K47/02 , A61K47/12 , A61K39/00
摘要： The present invention relates to novel liquid pharmaceutical compositions of adalimumab, which include adalimumab or a biosimilar thereof, an acetate buffering agent/system such as sodium acetate/acetic acid, and a sugar stabiliser such as trehalose. Such a combination of components furnishes formulations having a stability (e.g. on storage and when exposed to stress) which is comparable to or an improvement upon those known in the art, and with fewer ingredients. Such advances will help adalimumab treatments to become more widely available at lower cost, and prolong the viability of pre-loaded delivery devices (e.g. pre-filled syringes) to reduce unnecessary waste of the drug.
-
公开(公告)号：US10772961B2
公开(公告)日：2020-09-15
申请号：US16694627
申请日：2019-11-25
摘要： The present invention relates to novel liquid pharmaceutical compositions of adalimumab, which include adalimumab or a biosimilar thereof, an histidine buffering agent such as histidine (or histidine buffer system such as histidine/imidiazolium-histidine), and a sugar stabiliser such as trehalose. Such a combination of components furnishes formulations having a stability (e.g. on storage and when exposed to stress) which is comparable to or an improvement upon those known in the art, and with fewer ingredients. Such advances will help adalimumab treatments to become more widely available at lower cost, and prolong the viability of pre-loaded delivery devices (e.g. pre-filled syringes) to reduce unnecessary waste of the drug.
-
公开(公告)号：US20210196824A1
公开(公告)日：2021-07-01
申请号：US17198983
申请日：2021-03-11
摘要： The present invention relates to novel liquid pharmaceutical compositions of adalimumab, which include adalimumab or a biosimilar thereof, an acetate buffering agent/system such as sodium acetate/acetic acid, and a sugar stabiliser such as trehalose. Such a combination of components furnishes formulations having a stability (e.g. on storage and when exposed to stress) which is comparable to or an improvement upon those known in the art, and with fewer ingredients. Such advances will help adalimumab treatments to become more widely available at lower cost, and prolong the viability of pre-loaded delivery devices (e.g. pre-filled syringes) to reduce unnecessary waste of the drug.
-
公开(公告)号：US20210023215A1
公开(公告)日：2021-01-28
申请号：US16990954
申请日：2020-08-11
IPC分类号： A61K39/395 , A61K9/00 , A61K47/18 , A61K47/26 , C07K16/24
摘要： The present invention relates to novel liquid pharmaceutical compositions of adalimumab, which include adalimumab or a biosimilar thereof, an histidine buffering agent such as histidine (or histidine buffer system such as histidine/imidiazolium-histidine), and a sugar stabiliser such as trehalose. Such a combination of components furnishes formulations having a stability (e.g. on storage and when exposed to stress) which is comparable to or an improvement upon those known in the art, and with fewer ingredients. Such advances will help adalimumab treatments to become more widely available at lower cost, and prolong the viability of pre-loaded delivery devices (e.g. pre-filled syringes) to reduce unnecessary waste of the drug.
-
公开(公告)号：US10426833B2
公开(公告)日：2019-10-01
申请号：US15313487
申请日：2015-05-15
IPC分类号： A61K39/395 , A61K9/00 , C07K16/24 , A61K47/12 , A61K47/26
摘要： The present invention relates to novel liquid pharmaceutical compositions of adalimumab, which include adalimumab or a biosimilar thereof, a citrate buffering agent/system such as sodium citrate/citric acid, and a sugar stabilizer such as trehalose. Such a combination of components furnishes formulations having a stability (e.g. on storage and when exposed to stress) which is comparable to or an improvement upon those known in the art, and with fewer ingredients. Such advances will help adalimumab treatments to become more widely available at lower cost, and prolong the viability of pre-loaded delivery devices (e.g. prefilled syringes) to reduce unnecessary waste of the drug.
-
-
-
-
-
-
-
-
-
搜索结果
22 条记录 (耗时 0.016 秒)
